Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
39 hedge funds and large institutions have $27.1M invested in Soleno Therapeutics in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 13 closing their positions.
0.29% less ownership
Funds ownership: 37.1% → 36.81% (-0.29%)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
17% less funds holding
Funds holding: 47 → 39 (-8)
19% less capital invested
Capital invested by funds: $33.6M → $27.1M (-$6.49M)
35% less call options, than puts
Call options by funds: $288K | Put options by funds: $444K
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$652K |
| 2 |
Two Sigma Advisers
New York
|
+$316K |
| 3 |
Two Sigma Investments
New York
|
+$137K |
| 4 |
BlackRock
New York
|
+$108K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$16.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG Americas Securities
New York
|
-$341K |
| 2 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$341K |
| 3 |
Renaissance Technologies
New York
|
-$338K |
| 4 |
Millennium Management
New York
|
-$222K |
| 5 |
E
Ergoteles
New York
|
-$182K |
SLNO Hedge Fund Activity: Q3 2021 in Review
39 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q3 2021, worth a combined $27.1M — down 19% from $33.6M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of SLNO and 5 opened new positions — a net loss of 8 holders — while 10 trimmed existing stakes and 9 added.
The largest buyer was Granite Point Capital Management, opening a new position worth an estimated $652K. The largest seller was SG Americas Securities, exiting entirely with an estimated $341K sold.
- 39 institutional investors held Soleno Therapeutics (SLNO) as of Q3 2021, down from 47 in Q2 2021.
- Funds reported $27.1M of Soleno Therapeutics stock for Q3 2021, down 19% quarter-over-quarter.
- 5 funds opened new Soleno Therapeutics positions in Q3 2021 and 13 closed out, a net change of -8 holders.
- The largest Soleno Therapeutics buyer in Q3 2021 was Granite Point Capital Management, an estimated $652K added.
- The largest Soleno Therapeutics seller in Q3 2021 was SG Americas Securities, an estimated $341K sold.
Based on aggregated 13F filings for Q3 2021.